OPKO Health
Market Cap
US$2.8b
Last Updated
2021/04/10 23:38 UTC
Data Sources
Company Financials +
Executive Summary
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. More Details
Rewards
Risk Analysis
OPK passed our risk checks.
Snowflake Analysis
Fair value with moderate growth potential.
Similar Companies
Share Price & News
How has OPKO Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OPK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: OPK's weekly volatility (10%) has been stable over the past year.
Market Performance
7 Day Return
-4.6%
OPK
-2.2%
US Biotechs
2.1%
US Market
1 Year Return
192.3%
OPK
31.5%
US Biotechs
56.3%
US Market
Return vs Industry: OPK exceeded the US Biotechs industry which returned 31.3% over the past year.
Return vs Market: OPK exceeded the US Market which returned 55.3% over the past year.
Shareholder returns
| OPK | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.6% | -2.2% | 2.1% |
| 30 Day | -5.9% | -4.2% | 2.4% |
| 90 Day | -5.0% | -5.5% | 6.1% |
| 1 Year | 192.3%192.3% | 33.6%31.5% | 59.1%56.3% |
| 3 Year | 39.8%39.8% | 26.9%21.1% | 65.7%55.1% |
| 5 Year | -61.3%-61.3% | 40.2%29.9% | 122.3%97.6% |
Long-Term Price Volatility Vs. Market
How volatile is OPKO Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
OPKO Health (NASDAQ:OPK) Shareholders Have Enjoyed An Impressive 253% Share Price Gain1 month ago | Simply Wall St
OPKO Health's (NASDAQ:OPK) Earnings Are Weaker Than They Seem1 month ago | Simply Wall St
We Might See A Profit From OPKO Health, Inc. (NASDAQ:OPK) SoonValuation
Is OPKO Health undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OPK ($4.18) is trading below our estimate of fair value ($16.74)
Significantly Below Fair Value: OPK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OPK is poor value based on its PE Ratio (87.6x) compared to the US Biotechs industry average (29.9x).
PE vs Market: OPK is poor value based on its PE Ratio (87.6x) compared to the US market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: OPK is poor value based on its PEG Ratio (3x)
Price to Book Ratio
PB vs Industry: OPK is good value based on its PB Ratio (1.7x) compared to the US Biotechs industry average (3.9x).
Future Growth
How is OPKO Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
29.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPK's forecast earnings growth (29.6% per year) is above the savings rate (2%).
Earnings vs Market: OPK's earnings (29.6% per year) are forecast to grow faster than the US market (18.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: OPK's revenue (1% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: OPK's revenue (1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPK's Return on Equity is forecast to be high in 3 years time
Past Performance
How has OPKO Health performed over the past 5 years?
-27.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OPK has high quality earnings.
Growing Profit Margin: OPK became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: OPK has become profitable over the past 5 years, growing earnings by -27.9% per year.
Accelerating Growth: OPK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: OPK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: OPK's Return on Equity (1.8%) is considered low.
Financial Health
How is OPKO Health's financial position?
Financial Position Analysis
Short Term Liabilities: OPK's short term assets ($523.2M) exceed its short term liabilities ($375.5M).
Long Term Liabilities: OPK's short term assets ($523.2M) exceed its long term liabilities ($426.0M).
Debt to Equity History and Analysis
Debt Level: OPK's debt to equity ratio (15%) is considered satisfactory.
Reducing Debt: OPK's debt to equity ratio has increased from 6.8% to 15% over the past 5 years.
Debt Coverage: OPK's debt is not well covered by operating cash flow (15.8%).
Interest Coverage: OPK's interest payments on its debt are not well covered by EBIT (2.5x coverage).
Balance Sheet
Dividend
What is OPKO Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OPK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OPK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OPK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OPK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OPK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.8yrs
Average management tenure
CEO
Phil Frost (84 yo)
14.08yrs
Tenure
US$1,405,200
Compensation
Dr. Phillip Frost, also known as Phil, M.D., Ph.D., has been Chief Executive Officer of Opko Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and General Partner of Frost Philli...
CEO Compensation Analysis
Compensation vs Market: Phil's total compensation ($USD1.41M) is below average for companies of similar size in the US market ($USD5.05M).
Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: OPK's management team is seasoned and experienced (7.8 years average tenure).
Board Members
Experienced Board: OPK's board of directors are seasoned and experienced ( 13.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OPK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
OPKO Health, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: OPKO Health, Inc.
- Ticker: OPK
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.801b
- Shares outstanding: 670.04m
- Website: https://www.opko.com
Number of Employees
Location
- OPKO Health, Inc.
- 4400 Biscayne Boulevard
- Miami
- Florida
- 33137
- United States
Listings
Biography
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostic...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/10 23:38 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.